Search Options Stock News and Analysis from Schaeffer's

Biopharma Stock Gaps Lower After Trial Disappoints

https://www.schaeffersresearch.com/content/news/2023/07/03/biopharma-stock-gaps-lower-after-trial-disappoints

7/3/2023 10:53 AM

AstraZeneca PLC (NASDAQ:AZN) is gapping lower today, after the biopharmaceutical name's lung cancer drug disappointed investors in a late-stage trial. At last glance, AZN was down 7.2% at $66.41 and...

Options Traders Target Pharma Stock on FDA Buzz

https://www.schaeffersresearch.com/content/options/2023/06/06/options-traders-target-pharma-stock-on-fda-buzz

6/6/2023 3:06 PM

Options traders are blasting pharma stock AstraZeneca PLC (NASDAQ:AZN) today, after the U.S. Food and Drug Administration (FDA) failed to find any safety issues with the company's experimental respi...

Stocks Eye Solid Weekly Gains Despite Election Jitters

https://www.schaeffersresearch.com/content/news/2022/11/11/stocks-eye-solid-weekly-gains-despite-election-jitters

11/11/2022 12:26 PM

Stocks largely brushed off Election Day jitters this week to nab sizable gains. It was not without any challenges, though -- the Dow Jones Industrial Average (DJI) snapped its three-day win streak ...

AstraZeneca Stock Surges on Upbeat Earnings, Forecast

https://www.schaeffersresearch.com/content/news/2022/11/10/astrazeneca-stock-surges-on-upbeat-earnings-forecast

11/10/2022 11:25 AM

AstraZeneca PLC (NASDAQ:AZN) stock is up 7% at $65.30 at last glance, after the biotech name posted an upbeat third-quarter report and raised forecast. The company posted earnings of 84 cents per shar...

AstraZeneca Stock Could Soon Break Higher According to Technical Setup

https://www.schaeffersresearch.com/content/options/2022/05/10/biopharma-stock-could-soon-break-higher

5/10/2022 2:00 PM

Biopharmaceutical stock AstraZeneca PLC (NASDAQ:AZN) settled around the $64.52 level on Friday, which also marks its $200 billion market cap as well as two prior highs in November 2021 and July 2020...

PEOPLE ALSO SEARCH FOR

-intraday-options-activity

IXIC

LLY